MedPath

Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units

Conditions
on Occurrence of Acurate Kidney Injury During Intensive Care Unit
Abnormalities of Urinary Analysis
Registration Number
NCT04459975
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

The actual COVID-19 epidemy is an unprecedented healthcare problem. Although acute respiratory distress syndrome is the main organ failure, acute kidney injury (AKI) has appeared to be more frequent and more severe than expected. Some data suggested a potential direct renal tropism of the virus, or undirect injury by "cytokine storm".

The aims of this study are:

1. To describe incidence, severity and mortality associated with AKI during covid-19 infection in ICU

2. To identify specific risk factors for AKI

3. To explore pathophysiologic mechanism of AKI during COVID-19 infection

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Confirmed COVID-19 infection (by qRT-PCR and/or TDM typical lesion)
  • Needing intensive care
Exclusion Criteria
  • End Stage Renal Disease patients (with pre-existent dialysis)
  • Intensive care support for less than 72h (transfer in conventional unit or death)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary endpoint is the incidence, the severity and the mortality associated with AKI during COVID-19 severe infection7 months

AKI will be defined according with KDIGO guidelines: increase in creatinine of more than 1,5 fold compared to baseline Severe CVOID-19 infection is defined as 1/ confirm COVID-19 infection (by TDM and/or qRT-PCR) 2/ Requirement of ICU support during more than 72h

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Intensive care units attached to the Hospices Civils de Lyon (HCL)

🇫🇷

Lyon, France

Intensive care units attached to the Hospices Civils de Lyon (HCL)
🇫🇷Lyon, France
Denis FOUQUE, Professor
Contact
+33 472 678 704
denis.fouque@chu-lyon.fr
Maxime EPSI
Contact
+33 472 678 704
maxime.espi@chu-lyon.fr

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.